Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) have earned a consensus recommendation of “Moderate Buy” from the eighteen analysts that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and fourteen have issued a buy rating on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $205.6667.

Several research firms recently weighed in on JAZZ. TD Cowen restated a “buy” rating on shares of Jazz Pharmaceuticals in a report on Thursday, January 29th. Wells Fargo & Company increased their target price on shares of Jazz Pharmaceuticals from $170.00 to $235.00 and gave the company an “overweight” rating in a research note on Tuesday, November 18th. Royal Bank Of Canada set a $194.00 price target on shares of Jazz Pharmaceuticals and gave the stock an “outperform” rating in a research note on Monday, November 17th. Needham & Company LLC upped their price target on shares of Jazz Pharmaceuticals from $210.00 to $235.00 and gave the company a “buy” rating in a report on Monday, January 12th. Finally, Wall Street Zen raised shares of Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, November 8th.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 77,500 shares of the stock in a transaction on Wednesday, November 26th. The stock was sold at an average price of $177.81, for a total value of $13,780,275.00. Following the sale, the director owned 393,332 shares in the company, valued at $69,938,362.92. This trade represents a 16.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Patricia Carr sold 4,660 shares of Jazz Pharmaceuticals stock in a transaction on Friday, December 5th. The stock was sold at an average price of $171.20, for a total value of $797,792.00. Following the sale, the chief accounting officer owned 7,012 shares of the company’s stock, valued at approximately $1,200,454.40. This trade represents a 39.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 123,791 shares of company stock valued at $21,991,850. Company insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Cardinal Capital Management boosted its position in Jazz Pharmaceuticals by 0.5% in the 4th quarter. Cardinal Capital Management now owns 14,538 shares of the specialty pharmaceutical company’s stock valued at $2,471,000 after buying an additional 66 shares during the period. EverSource Wealth Advisors LLC raised its stake in shares of Jazz Pharmaceuticals by 9.0% during the third quarter. EverSource Wealth Advisors LLC now owns 983 shares of the specialty pharmaceutical company’s stock valued at $130,000 after acquiring an additional 81 shares in the last quarter. Tectonic Advisors LLC boosted its holdings in shares of Jazz Pharmaceuticals by 1.5% in the third quarter. Tectonic Advisors LLC now owns 5,626 shares of the specialty pharmaceutical company’s stock valued at $742,000 after purchasing an additional 82 shares during the period. Pinnacle Associates Ltd. grew its stake in Jazz Pharmaceuticals by 0.7% in the fourth quarter. Pinnacle Associates Ltd. now owns 11,203 shares of the specialty pharmaceutical company’s stock worth $1,905,000 after purchasing an additional 83 shares in the last quarter. Finally, Teacher Retirement System of Texas increased its holdings in Jazz Pharmaceuticals by 0.6% during the 2nd quarter. Teacher Retirement System of Texas now owns 15,560 shares of the specialty pharmaceutical company’s stock worth $1,651,000 after purchasing an additional 90 shares during the period. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Trading Up 1.4%

Shares of JAZZ stock opened at $165.50 on Friday. The company has a market cap of $10.06 billion, a PE ratio of -27.27, a price-to-earnings-growth ratio of 0.88 and a beta of 0.26. Jazz Pharmaceuticals has a 1 year low of $95.49 and a 1 year high of $182.99. The stock’s 50 day simple moving average is $167.86 and its two-hundred day simple moving average is $145.32. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.65 and a quick ratio of 1.44.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.